May 16 (Reuters) - ONXEO SA C4X.PA :
* CASH POSITION OF EUR 9.2 MILLION AT MARCH 31, 2018, SUFFICIENT TO SUPPORT COMPANY'S
OPERATIONS
UNTIL MID-2019
* DEVELOPMENT OF LEAD PRODUCT CANDIDATE, ASIDNA™, FOR THE TREATMENT OF ADVANCED SOLID
TUMORS,
PROGRESSING ACCORDING TO PLAN
* DRIIV PHASE I CLINICAL TRIAL ONGOING
* INTERIM RESULTS EXPECTED IN H2 2018
* Q1 REVENUES EUR 687,00
Source text for Eikon: ID:nBw7CPC76a
Further company coverage: C4X.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))